Document Detail

The "no treatment" approach to ocular hypertension.
MedLine Citation:
PMID:  7008229     Owner:  NLM     Status:  MEDLINE    
Should patients with ocular hypertension be treated to prevent glaucomatous visual field loss? Three considerations suggest that for most patients the answer is no. First, the average risk of visual field loss in untreated ocular hypertension is small. Population surveys and prospective studies indicate that no more than about one of every nine persons with intraocular pressures higher than 20 mm Hg will develop a visual field defect. Secondly, treatment of ocular hypertension to lower intraocular pressure is unproven efficacy in preventing visual field defects. Thirdly, adverse reactions to glaucoma therapy occur frequently and are sometimes serious. Although pressure reduction may be indicated for some patients who possess certain risk factors which make them especially susceptible to glaucomatous damage, for most patients "no treatment" is the best management. Untreated patients must be observed carefully with periodic visual field and optic disc examinations.
C D Phelps
Related Documents :
3748589 - Pressure-pain threshold in human temporal region. evaluation of a new pressure algometer.
7387959 - Timolol in operated closed-angle glaucoma.
19210139 - Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled ...
10926979 - Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocul...
1356429 - Diurnal intraocular pressure variations: an analysis of 690 diurnal curves.
6746239 - Proptosis and increase of intraocular pressure in voluntary lid fissure widening.
1953849 - Advantages of handsewn over stapled bowel anastomosis.
10423109 - The importance of drug combinations for effective control of hypertension.
9203889 - The effect of single-handed cricoid pressure on neck movement after applying manual in-...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Survey of ophthalmology     Volume:  25     ISSN:  0039-6257     ISO Abbreviation:  Surv Ophthalmol     Publication Date:    1980 Nov-Dec
Date Detail:
Created Date:  1981-04-21     Completed Date:  1981-04-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0404551     Medline TA:  Surv Ophthalmol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  175-82     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carbonic Anhydrase Inhibitors / adverse effects
Epinephrine / adverse effects
Glaucoma / drug therapy,  surgery,  therapy*
Intraocular Pressure* / drug effects
Middle Aged
Miotics / adverse effects
Postoperative Complications
Scotoma / etiology
Timolol / adverse effects
Reg. No./Substance:
0/Carbonic Anhydrase Inhibitors; 0/Miotics; 26839-75-8/Timolol; 51-43-4/Epinephrine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk factors favoring the development of glaucomatous visual field loss in ocular hypertension.
Next Document:  Computerized intravenous arteriography: a technique for visualizing the peripheral vascular system.